Avian influenza: the next pandemic?

Clinical Microbiology Newsletter

Volumn 28, Issue 13, 2006, Pages 97-101

  Moellering Jr , Robert C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; BACTERIAL PNEUMONIA; BIRD; DRUG EFFICACY; EPIDEMIC; HUMAN; INCUBATION TIME; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LABORATORY DIAGNOSIS; MYOSITIS; NONHUMAN; OUTCOME ASSESSMENT; RISK ASSESSMENT; TREATMENT OUTCOME; VACCINATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 33745449729     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2006.06.001     Document Type: Article

References (14)

1. WHO. The Writing Committee of the World Health Organization Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353 (2005) 1374-1385
2. WHO. Update: Influenza activity - United States, March 19-25, 2006. Morb. Mortal. Wkly. Rep. 55 (2006) 368-370
3. Treanor J.J. Influenza virus. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 6th ed. (2005), Elsevier, Philadelphia 2060-2085
4. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353 (2005) 1363-1373
5. Puzelli S. Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. J. Infect. Dis. 192 (2005) 1318-1322
6. Hayden F., and Croisier A. Transmission of avian influenza viruses to and between humans. J. Infect. Dis. 192 (2005) 1311-1314
7. Tiensin T. Highly pathogenic avian influenza H5N1, Thailand, 2004. Emerg. Infect. Dis. 11 (2005) 1664-1672
8. World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11 (2005) 1515-1521
9. de Jong M.D. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005) 2667-2672
10. Schwartz B., and Gellin B. Vaccination strategies for an influenza pandemic. J. Infect. Dis. 191 (2005) 1207-1209
11. Lipatov A.S. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J. Infect. Dis. 191 (2005) 1216-1220
12. Epstein S.L. Prior H1N1 influenza infection and susceptibility of Cleveland family study participants during the H2N2 pandemic of 1957: an experiment of nature. J. Infect. Dis. 193 (2006) 49-53
13. Tumpey T.M. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310 (2005) 77-80
14. Lipsitch M., and Bloom B.R. Avian flu preparing for a pandemic. Harvard Pub. Health Rev. Winter 2006 (2006) 4-7